Projecting the economic burden of type 1 and type 2 diabetes mellitus in Germany from 2010 until 2040
Uloženo v:
| Název: | Projecting the economic burden of type 1 and type 2 diabetes mellitus in Germany from 2010 until 2040 |
|---|---|
| Autoři: | Dina Voeltz, Maximilian Vetterer, Esther Seidel-Jacobs, Ralph Brinks, Thaddäus Tönnies, Annika Hoyer |
| Zdroj: | Popul Health Metr Population Health Metrics, Vol 22, Iss 1, Pp 1-11 (2024) |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2024. |
| Rok vydání: | 2024 |
| Témata: | Male, Adult, Adolescent, Epidemiology, Economic burden of disease, Computer applications to medicine. Medical informatics, R858-859.7, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Cost of Illness, Germany, Diabetes Mellitus, Type 2/epidemiology [MeSH], Infant, Newborn [MeSH], Type 2 diabetes, Cost of Illness [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Type 1 diabetes, Germany/epidemiology [MeSH], Infant [MeSH], Male [MeSH], Diabetes Mellitus, Type 1/economics [MeSH], Cost analysis, Prevalence [MeSH], Child [MeSH], Health Care Costs [MeSH], Adolescent [MeSH], Female [MeSH], Diabetes Mellitus, Type 1/epidemiology [MeSH], Adult [MeSH], Humans [MeSH], Healthcare costs, Incidence [MeSH], Middle Aged [MeSH], Research, Young Adult [MeSH], Projection, Diabetes Mellitus, Type 2/economics [MeSH], Child, Preschool [MeSH], Prevalence, Humans, Child, Aged, Aged, 80 and over, Incidence, Infant, Newborn, Infant, Health Care Costs, Middle Aged, 3. Good health, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Child, Preschool, Female, Public aspects of medicine, RA1-1270 |
| Popis: | Background The aim is to estimate age- and sex-specific direct medical costs related to diagnosed type 1 and type 2 diabetes in Germany between 2010 and 2040. Methods Based on nationwide representative epidemiological routine data from 2010 from the statutory health insurance in Germany (almost 80% of the population’s insurance) we projected age- and sex-specific healthcare expenses for type 1 and 2 diabetes considering future demographic, disease-specific and cost trends. We combine per capita healthcare cost data (obtained from aggregated claims data from an almost 7% random sample of all German people with statutory health insurance) together with the demographic structure of the German population (obtained from the Federal Statictical Office), diabetes prevalence, incidence and mortality. Direct per capita costs, total annual costs, cost ratios for people with versus without diabetes and attributable costs were estimated. The source code for running the analysis is publicly available in the open-access repository Zenodo. Results In 2010, total healthcare costs amounted to more than €1 billion for type 1 and €28 billion for type 2 diabetes. Depending on the scenario, total annual expenses were projected to rise remarkably until 2040 compared to 2010, by 1–281% for type 1 (€1 to €4 billion) and by 8–364% for type 2 diabetes (€30 to €131 billion). In a relatively probable scenario total costs amount to about €2 and €79 billion for type 1 and type 2 diabetes in 2040, respectively. Depending on annual cost growth (1% p.a. as realistic scenario vs. 5% p.a. as very extreme setting), we estimated annual per capita costs of €6,581 to €12,057 for type 1 and €5,245 to €8,999 for type 2 diabetes in 2040. Conclusions Diabetes imposes a large economic burden on Germany which is projected to increase substantially until 2040. Temporal trends in the incidence and cost growth are main drivers of this increase. This highlight the need for urgent action to prepare for the potential development and mitigate its consequences. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1478-7954 |
| DOI: | 10.1186/s12963-024-00337-x |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39026351 https://doaj.org/article/c251bebd63e0487a9aec15517b081c99 https://repository.publisso.de/resource/frl:6502351 |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (http://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| Přístupové číslo: | edsair.doi.dedup.....daf38917534beb98bee0ba283cd0c5ec |
| Databáze: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background The aim is to estimate age- and sex-specific direct medical costs related to diagnosed type 1 and type 2 diabetes in Germany between 2010 and 2040. Methods Based on nationwide representative epidemiological routine data from 2010 from the statutory health insurance in Germany (almost 80% of the population’s insurance) we projected age- and sex-specific healthcare expenses for type 1 and 2 diabetes considering future demographic, disease-specific and cost trends. We combine per capita healthcare cost data (obtained from aggregated claims data from an almost 7% random sample of all German people with statutory health insurance) together with the demographic structure of the German population (obtained from the Federal Statictical Office), diabetes prevalence, incidence and mortality. Direct per capita costs, total annual costs, cost ratios for people with versus without diabetes and attributable costs were estimated. The source code for running the analysis is publicly available in the open-access repository Zenodo. Results In 2010, total healthcare costs amounted to more than €1 billion for type 1 and €28 billion for type 2 diabetes. Depending on the scenario, total annual expenses were projected to rise remarkably until 2040 compared to 2010, by 1–281% for type 1 (€1 to €4 billion) and by 8–364% for type 2 diabetes (€30 to €131 billion). In a relatively probable scenario total costs amount to about €2 and €79 billion for type 1 and type 2 diabetes in 2040, respectively. Depending on annual cost growth (1% p.a. as realistic scenario vs. 5% p.a. as very extreme setting), we estimated annual per capita costs of €6,581 to €12,057 for type 1 and €5,245 to €8,999 for type 2 diabetes in 2040. Conclusions Diabetes imposes a large economic burden on Germany which is projected to increase substantially until 2040. Temporal trends in the incidence and cost growth are main drivers of this increase. This highlight the need for urgent action to prepare for the potential development and mitigate its consequences. |
|---|---|
| ISSN: | 14787954 |
| DOI: | 10.1186/s12963-024-00337-x |